company featured image
  • Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, oral treatments of cancer, acute kidney injury and other serious illnesses.
  • Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.

 

READ MORE

pipeline featured image
  • Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, breast cancer, pancreatic cancer, and prevention of acute kidney injury in seriously ill patients.

 

READ MORE

doctor viewing vaccine

September 2023 –Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.

 

August 2023 –Cantex Pharmaceuticals announced the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases.

 

August 2023 – Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily.

 

READ ALL NEWS

CANTEX IS DEVELOPING AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA, BRAIN METASTASES, BREAST CANCER, PANCREATIC CANCER AND PREVENTION OF ACUTE KIDNEY INJURY IN SERIOUSLY ILL PATIENTS.